CA3192030A1 - Annexin a1 n-terminal peptide formulations and methods - Google Patents

Annexin a1 n-terminal peptide formulations and methods

Info

Publication number
CA3192030A1
CA3192030A1 CA3192030A CA3192030A CA3192030A1 CA 3192030 A1 CA3192030 A1 CA 3192030A1 CA 3192030 A CA3192030 A CA 3192030A CA 3192030 A CA3192030 A CA 3192030A CA 3192030 A1 CA3192030 A1 CA 3192030A1
Authority
CA
Canada
Prior art keywords
pharmaceutical formulation
liquid pharmaceutical
solution
formulation according
annexin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3192030A
Other languages
English (en)
French (fr)
Inventor
Jens Thostrup Bukrinski
Pernille Sonderby Tuelung
Mette Hamborg Jensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ResoTher Pharma AS
Original Assignee
ResoTher Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ResoTher Pharma AS filed Critical ResoTher Pharma AS
Publication of CA3192030A1 publication Critical patent/CA3192030A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA3192030A 2020-08-21 2021-08-20 Annexin a1 n-terminal peptide formulations and methods Pending CA3192030A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20192142 2020-08-21
EP20192142.6 2020-08-21
PCT/EP2021/073186 WO2022038281A1 (en) 2020-08-21 2021-08-20 Annexin a1 n-terminal peptide formulations and methods

Publications (1)

Publication Number Publication Date
CA3192030A1 true CA3192030A1 (en) 2022-02-24

Family

ID=72193322

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3192030A Pending CA3192030A1 (en) 2020-08-21 2021-08-20 Annexin a1 n-terminal peptide formulations and methods

Country Status (10)

Country Link
US (2) US20230295255A1 (cg-RX-API-DMAC10.html)
EP (3) EP4595950A3 (cg-RX-API-DMAC10.html)
JP (1) JP2023539476A (cg-RX-API-DMAC10.html)
CN (1) CN116323649A (cg-RX-API-DMAC10.html)
AU (1) AU2021327733A1 (cg-RX-API-DMAC10.html)
CA (1) CA3192030A1 (cg-RX-API-DMAC10.html)
ES (1) ES3031633T3 (cg-RX-API-DMAC10.html)
HU (1) HUE071875T2 (cg-RX-API-DMAC10.html)
PL (1) PL4200319T3 (cg-RX-API-DMAC10.html)
WO (2) WO2022038258A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024003338A1 (en) * 2022-06-30 2024-01-04 Resother Pharma A/S Annexin a1 liquid pharmaceutical composition

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3031633T3 (en) * 2020-08-21 2025-07-10 Resother Pharma As Annexin a1 n-terminal peptide formulations and methods
EP4680262A1 (en) 2023-03-13 2026-01-21 Resother Pharma A/S Annexin a1 delayed dosing
AU2024234229A1 (en) 2023-03-13 2025-09-25 Resother Pharma A/S Annexin a1 administration regime
WO2025083394A1 (en) 2023-10-16 2025-04-24 Therakind Limited Antimicrobial use of annexin a1 protein
WO2025083393A1 (en) 2023-10-16 2025-04-24 Therakind Limited Antimicrobial use of peptides derived from annexin a1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
BR112013032088B1 (pt) 2011-06-15 2020-11-24 Resother Pharma Aps produtos farmacêuticos anti-inflamatórios
WO2013053888A1 (en) * 2011-10-14 2013-04-18 Baxter International Inc. Protein purification by anion exchange chromatography
HUE052977T2 (hu) 2014-04-22 2021-06-28 Txp Pharma Gmbh Elágazó szénláncú aminosav-próbával rendelkezõ peptid analóg(ok)
CN110302176A (zh) * 2019-06-25 2019-10-08 中国人民解放军陆军军医大学 一种抗炎多肽纳米药物及制备方法
ES3031633T3 (en) * 2020-08-21 2025-07-10 Resother Pharma As Annexin a1 n-terminal peptide formulations and methods
US20250345392A1 (en) * 2022-06-30 2025-11-13 Resother Pharma A/S Annexin a1 liquid pharmaceutical composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024003338A1 (en) * 2022-06-30 2024-01-04 Resother Pharma A/S Annexin a1 liquid pharmaceutical composition

Also Published As

Publication number Publication date
EP4200319C0 (en) 2025-04-16
EP4200319B1 (en) 2025-04-16
AU2021327733A9 (en) 2023-04-27
US20230295255A1 (en) 2023-09-21
EP4200319A1 (en) 2023-06-28
WO2022038258A1 (en) 2022-02-24
AU2021327733A1 (en) 2023-04-20
EP4595950A2 (en) 2025-08-06
JP2023539476A (ja) 2023-09-14
ES3031633T3 (en) 2025-07-10
PL4200319T3 (pl) 2025-08-18
HUE071875T2 (hu) 2025-09-28
CN116323649A (zh) 2023-06-23
EP4595950A3 (en) 2025-10-29
EP4200320A1 (en) 2023-06-28
US20240041977A1 (en) 2024-02-08
WO2022038281A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
EP4200319B1 (en) Annexin a1 n-terminal peptide formulations and methods
JP2002524514A (ja) タンパク質製剤
EP3065765B1 (en) Use of il-22 dimers in manufacture of medicaments for treating pancreatitis
CA2945812C (en) Trail receptor agonists for treatment of fibrotic diseases
CN106687126B (zh) 因子viii制剂
AU2021399904B2 (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
EP4262745B1 (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
US20230405088A1 (en) Pharmaceutical Composition of GLP-1/GLP-2 Dual Agonists
JP6943858B2 (ja) コラーゲン７組成物及びそれを用いる方法
KR20230117342A (ko) 펩타이드 제제 및 이의 안과적 용도
US8895503B2 (en) Pharmaceutical composition for transnasal administration of peptide hormones or cytokines
CN115605218B (zh) 用于治疗大疱性表皮松解症的归巢肽引导的核心蛋白聚糖缀合物
RU2852511C1 (ru) Фармацевтическая композиция двойных агонистов glp-1/glp-2
RU2855486C1 (ru) Фармацевтическая композиция двойных агонистов glp-1/glp-2
RU2855506C1 (ru) Фармацевтическая композиция двойных агонистов glp-1/glp-2
RU2833459C2 (ru) Составы аналогов глюкагоноподобного пептида-2 (glp-2)
EA026073B1 (ru) Состав бычьего гранулоцитарного колониестимулирующего фактора и способ лечения с его использованием
JP2001522814A (ja) 増大されたｉｇｆ−ｉ溶解性を提供する組成物
HK40095698A (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
HK40095698B (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
EA045982B1 (ru) СТАБИЛЬНЫЙ ЛИОФИЛИЗИРОВАННЫЙ СОСТАВ НА ОСНОВЕ G-CSF, СЛИТОГО С ГИБРИДНЫМ Fc
WO2022015590A1 (en) Fibroblast growth factor 7 peptide
KR20180122144A (ko) 인슐린 비강 전달용 제제

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240809

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240809

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250716

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250716

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250716

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250716

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250716

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250923

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250923

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250923

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250923

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250923